Prof. Dr. Mutlu Demiray

Team Lead

Internal Medicine and Medical Oncology Specialist · Genomic Oncology
Director, Medicana Personalized Cancer Treatment Center

As a medical professional deeply committed to advancing patient care and transforming the landscape of oncology, Prof. Dr. Mutlu Demiray's clinical focus is precision oncology. Throughout his career he has devoted himself to unraveling the intricacies of cancer biology and harnessing Next-Generation Sequencing (NGS) technologies to transform cancer treatment.

His primary focus is the meticulous analysis of patients' NGS results, which allows him to unlock invaluable insights into the unique biology of their tumors. With this personalized approach he designs tailored treatment regimens that address the specific molecular aberrations driving each individual's cancer, maximizing therapeutic efficacy while minimizing adverse effects.

His passion for precision oncology drives him to explore novel therapeutic avenues, collaborate with multidisciplinary teams, and contribute significantly to the ever-evolving landscape of personalized cancer care.

Professional career

2014 – Present

Prof. Dr. · Director, Personalized Cancer Treatment Center

Medicana Health Group

2011 – 2014

Assoc. Prof. Dr.

OSM Middle East Hospital

2010 – 2011

Assoc. Prof. Dr.

İstanbul Italian Hospital

2007 – 2010

Assoc. Prof. Dr.

Medical Park Bursa Hospital

2006 – 2007

Assoc. Prof. Dr.

Ali Osman Sönmez Oncology Hospital

2004 – 2006

Specialist Dr.

Uludağ University

Academic career

2014

Professor (Prof. Dr.)

2006

Associate Professor (Doç. Dr.)

2004

Medical Oncology Specialty

Uludağ University Faculty of Medicine, Bursa

2000

Internal Medicine Specialty

Uludağ University Faculty of Medicine, Bursa

1995

Doctor of Medicine (MD)

Akdeniz University Faculty of Medicine, Antalya

Areas of work

Personalized Cancer Treatment and Comprehensive Genomic Profiling

Designing tumor-specific, personalized treatment strategies for each patient on the basis of their genomic profile.

Targeted Therapy and Immunotherapy

Identifying targeted drug and immunotherapy options in the light of molecular findings.

Molecular Tumor Boards (MTBs)

Evaluating cases on international molecular tumor boards and contributing to treatment decisions.

Education and International Consulting

Sharing experience as a speaker at international meetings and advising physicians on genomic-profiling-based treatment design.

Scientific memberships

ASCO – American Society of Clinical OncologyEACR – European Association for Cancer ResearchESHO – European Society of Hyperthermic OncologyGHT – Deutsche Gesellschaft für Hyperthermie e.V.Türk Tıbbi Onkoloji Derneği (Turkish Society of Medical Oncology)

Scientific publications

Articles published in international peer-reviewed journals, citations, and the latest academic record can be accessed via the link below.

International network

For multidisciplinary projects in precision oncology, Molecular Tumor Board (MTB) partnerships, and professional contact, you can connect via the LinkedIn profile.